



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

## Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews

journal homepage: [www.elsevier.com/locate/dsx](http://www.elsevier.com/locate/dsx)

## Letter to the Editor

## Letter to the editor in response to article: “Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.)



Dear Sir:

As of today's reports, the global number of confirmed cases of COVID-19 has surpassed 150,000. The number of known cases is increasing by several thousand every day. On March 11, 2020, WHO publicly characterized COVID-19 as a pandemic. The issue is of serious concern and deserves momentous attention.

Coronaviruses are a family of viruses that cause respiratory illnesses. Most of them cause illness in animals, but seven known types of coronaviruses cause illness in humans. The coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2) is one of those viruses – it causes the illness currently known as Coronavirus Disease-2019 (COVID-19).

Though we are still learning what exactly puts someone at greater risk of developing a severe illness with COVID-19, early information indicates older patients and those with chronic medical conditions such as hypertension, diabetes and cardio-cerebrovascular diseases may be at higher risk [1–3]. Infection caused by COVID-19 is likely to disturb metabolic regulation. Diabetic patients with COVID-19 may face an altered immune response on the background of an already compromised health status owing to the diabetes-related complications and/or aging.

The most important findings in patients with hyperglycemia and a viral infection were significant worsening of symptoms, which implies greater morbidity in these patients when compared to those without diabetes [3]. However, the pathophysiology of this association remains uncertain. It is not known whether hyperglycemia changes the virulence of the infection, or if the virus modifies the glycemic metabolism. What we know is that diabetic patients are more susceptible to infection, and this can impact on glucose metabolism [4]. DM is not just a disorder of glucose metabolism, but a chronic inflammatory condition characterized by multiple changes in lipid, carbohydrate and protein profiles [5]. Such inflammatory processes are due to hyperglycemia which leads to increased synthesis of glycosylation end products (AGEs), activates macrophages and other cells of the immune system, increase oxidative stress and promote the synthesis of pro-inflammatory cytokines, besides stimulating the synthesis of adhesion molecules that facilitate inflammation in the tissues [5]. The inflammatory process and its complications might provide a higher propensity to infections or a greater severity of these conditions. Another important issue is how this inflammatory and immune response occur in diabetic patients who acquire a viral infection, as well as whether the virus itself interferes with insulin secretion or the

glycemic control.

At this stage, the biological mechanism of the relationship between COVID-19 and diabetes is not known, but the association for the severity of cases and death is pronounced. We need to develop a hypothesis to explain the causal path underlying the more severe clinical presentation of COVID-19 infection and subsequent death in diabetic patients. Biochemical tests are also essential to clarify the molecular pathophysiology involved.

The association of COVID-19 and DM is of substantial public health importance and deserves proper attention, since a large and diverse population is being affected globally. Nowadays this comorbidity poses a relevant threat to human health, and prospective well-designed studies to elucidate the biological mechanism and the best clinical management of this association are urgently needed.

## References

- [1] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with Acute respiratory distress Syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020.
- [2] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol* 2020.
- [3] Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. *Diabetes & Metabolic Syndrome. Clin Res Rev* 2020;14:211–2.
- [4] Knapp S. Diabetes and infection: is there a link?—A mini-review. *Gerontology* 2013;59(2):99–104.
- [5] Abregú AV, Carrizo TR, Díaz El, Velarde MS, Fonio MC, Bazán MC. Subclinical inflammation in children and adolescents with type 1 diabetes. *Acta Biochim Clin Latinoam* 2015;49:393–8.

Akhtar Hussain\*

NORD University, Norway

Faculty of Medicine, Federal University of Ceará (FAMED-UFC), Brazil

International Diabetes Federation (IDF), Belgium

Diabetes Asian Study Group (DASG), Qatar

Nayla Cristina do Vale Moreira  
University of Oslo, Norway

Faculty of Medicine, Federal University of Ceará (FAMED-UFC), Brazil

\* Corresponding author.

E-mail address: [hussain.akhtar@nord.no](mailto:hussain.akhtar@nord.no) (A. Hussain).